| 1997 |
GPP130 (GOLIM4) is a type II integral membrane protein localized to the cis/medial Golgi with an unusually acidic lumenal domain and multiple coiled-coil regions. Overexpression causes accumulation in endocytic vesicles, and chloroquine treatment reversibly redistributes endogenous GPP130 to endocytic vesicles, demonstrating that its Golgi targeting is saturable and pH-sensitive, involving a retrieval mechanism for return to the Golgi. |
cDNA sequencing, overexpression, chloroquine treatment with immunofluorescence and electron microscopy, subcellular fractionation |
Molecular biology of the cell |
High |
9201717
|
| 2007 |
GPP130 cycling is regulated at multiple stages: intra-Golgi cycling, trans-Golgi to endosome transport, and endosome-to-Golgi transport. pH perturbation (monensin) most strongly affects the trans-Golgi, the most acidic portion of the Golgi apparatus. |
Quantitative fluorescence microscopy with Shiga-like toxin B fragment as trafficking probe, tsO45-GFP as secretory marker, simulations of trafficking kinetics |
Traffic (Copenhagen, Denmark) |
Medium |
17605763
|
| 2010 |
Extracellular manganese (Mn) induces rapid redistribution of GPP130 from the cis-Golgi to multivesicular bodies via a Rab7-dependent pathway, followed by lysosomal degradation. The lumenal stem domain of GPP130 acts as a Mn sensor and is required and sufficient to confer Mn sensitivity to another cis-Golgi protein. The cytoplasmic domain is dispensable. GPP130 must be targeted to the cis-Golgi for the Mn response to occur. |
Immunofluorescence, domain deletion/swap experiments, Rab7 dominant-negative inhibition, live-cell imaging, pulse-chase degradation assays |
Molecular biology of the cell |
High |
20130081
|
| 2013 |
GPP130 directly binds the B subunit of Shiga toxin (STx) and STx1 via a seven-residue stretch in its lumenal stem domain adjacent to the transmembrane domain. This interaction is required for retrograde endosome-to-Golgi trafficking of STx/STx1. STx2 B subunit does not bind GPP130, explaining why Mn-induced GPP130 down-regulation fails to block STx2 trafficking. |
Pulldown with purified toxin B subunits, mutagenesis of GPP130 stem domain and toxin residues, cell-based Shiga toxin trafficking assays |
Molecular biology of the cell |
High |
23761068
|
| 2013 |
GPP130 degradation in response to Mn is specific to Mn among transition metals tested (cobalt, copper, iron, nickel, zinc did not induce degradation) and occurs at sub-micromolar extracellular Mn concentrations without detectable increases in intracellular Mn, demonstrating exquisite selectivity of the GPP130 Mn-sensing mechanism in neuronal cells and in vivo in rat brain. |
Immunofluorescence quantification in AF5 cells, western blot, in vivo rat subchronic Mn exposure model |
Synapse (New York, N.Y.) |
Medium |
23280773
|
| 2017 |
Mn-induced exit of GPP130 from the trans-Golgi network toward lysosomes is mediated by the sorting receptor sortilin, which interacts with the lumenal stem domain of GPP130. Mn causes GPP130 to oligomerize/aggregate in the Golgi, and sortilin sorts these complexes for lysosomal delivery. In contrast, FM-domain-induced lysosomal trafficking of galactosyltransferase was sortilin-independent. |
Sortilin knockdown, Co-IP/interaction assays, domain deletion experiments, self-interacting FM domain aggregation system, immunofluorescence |
Molecular biology of the cell |
High |
28768823
|
| 2021 |
RBFOX2 binds a GGAA motif in exon-7 of GOLIM4 pre-mRNA and promotes inclusion of exon-7, generating the long isoform GOLIM4-L. GOLIM4-L and RBFOX2 maintain Golgi apparatus organization and influence vesicle-mediated transport. RAB26 interacts with GOLIM4 and mediates its tumorigenic effects in NPC cells. |
Transcriptome splicing profiling, RBFOX2 knockdown/overexpression rescue experiments, Co-IP (GOLIM4-RAB26 interaction), luciferase splicing reporter, immunofluorescence of Golgi organization |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) |
Medium |
34180133
|
| 2025 |
GPP130 is a substrate of proprotein convertases PC7 (PCSK7) and Furin, which cleave/shed GPP130 into a membrane-bound N-terminal product and secreted C-terminal fragments. GPP130 overexpression increases cell proliferation in A549, SKOV3, and HeLa cells, and this proliferative activity is enhanced upon cleavage by PC7 and/or Furin. |
Cell-based cleavage assays, overexpression and knockdown, proliferation assays, western blot for cleavage products |
International journal of molecular sciences |
Medium |
40649939
|
| 2025 |
Monensin increases Golgi lumenal pH, inducing rapid exocytosis of GOLIM4 from the Golgi. GOLIM4 regulates cell motility and adhesion by modulating post-Golgi trafficking of Talin 1 (TLN1), an essential focal adhesion component. Both GOLIM4 and TLN1 are direct targets of microRNA-200b, which is suppressed during EMT. |
Monensin treatment with live-cell imaging, GOLIM4 and TLN1 knockdown, migration assays, microRNA-200b target validation, Golgi pH measurement |
Proceedings of the National Academy of Sciences of the United States of America |
Medium |
40632561
|
| 2024 |
IRE1α regulates GOLIM4 expression via the XBP1s transcription factor downstream of ER stress. GOLIM4 silencing reduces surface expression of MHC class I molecules, growth factor receptors (PDGFRA, IL13RA2), and adhesion/migration proteins (CD44, CD54, NCAM1, ITGB1, CD90) without affecting their mRNA levels, demonstrating that GOLIM4 controls post-transcriptional surface trafficking of these molecules. GOLIM4 silencing impairs glioblastoma cell-cell adhesion and migration. |
IRE1 inhibition, XBP1s overexpression, GOLIM4 siRNA knockdown, flow cytometry for surface protein expression, qRT-PCR to exclude transcriptional effects, cell adhesion and migration assays |
bioRxivpreprint |
Medium |
bio_10.1101_2024.10.22.619629
|
| 2021 |
miR-105-3p directly targets the GOLIM4 3'UTR (validated by luciferase reporter assay) and suppresses GOLIM4 expression, promoting breast cancer cell proliferation and metastasis. |
Luciferase reporter assay, GOLIM4 silencing rescue experiment, CCK-8, Transwell, TUNEL assays |
BMC cancer |
Low |
33722196
|